Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. Fundamental Analysis
Ono Pharmaceutical Co., Ltd. (4528.T) shows moderate financial fundamentals with a PE ratio of 17.79, profit margin of 12.25%, and ROE of 7.80%. The company generates $509.3B in annual revenue with strong year-over-year growth of 12.41%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 4528.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4528.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent4528.T trades at attractive valuation levels.
Growth Score
Excellent4528.T delivers strong and consistent growth momentum.
Financial Health Score
Excellent4528.T maintains a strong and stable balance sheet.
Profitability Score
Weak4528.T struggles to sustain strong margins.
Key Financial Metrics
Is 4528.T Expensive or Cheap?
P/E Ratio
4528.T trades at 17.79 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 4528.T's PEG of 0.62 indicates potential undervaluation.
Price to Book
The market values Ono Pharmaceutical Co., Ltd. at 1.32 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.85 times EBITDA. This is generally considered low.
How Well Does 4528.T Make Money?
Net Profit Margin
For every $100 in sales, Ono Pharmaceutical Co., Ltd. keeps $12.25 as profit after all expenses.
Operating Margin
Core operations generate 16.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.80 in profit for every $100 of shareholder equity.
ROA
Ono Pharmaceutical Co., Ltd. generates $5.75 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ono Pharmaceutical Co., Ltd. produces operating cash flow of $125.63B, showing steady but balanced cash generation.
Free Cash Flow
Ono Pharmaceutical Co., Ltd. generates strong free cash flow of $119.27B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $253.81 in free cash annually.
FCF Yield
4528.T converts 10.74% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.79
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.62
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.18
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.16
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How 4528.T Stacks Against Its Sector Peers
| Metric | 4528.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.79 | 28.25 | Better (Cheaper) |
| ROE | 7.80% | 780.00% | Weak |
| Net Margin | 12.25% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.16 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 3.02 | 4.66 | Strong Liquidity |
| ROA | 5.75% | -14687.00% (disorted) | Weak |
4528.T outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ono Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
459.56%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
697.83%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
432.47%
Industry Style: Defensive, Growth, Innovation
High Growth